High-dose Zevalin with stem cell transplant may benefit NHL patients

10/21/2008 | RTT News

A study showed that 83% of patients with relapsed/refractory or high-risk aggressive non-Hodgkin's lymphoma were disease-free 30 months after receiving high-dose Zevalin and undergoing a tandem stem cell transplant. The findings add to evidence that "Zevalin at higher than FDA approved doses with a stem cell rescue may provide an added clinical benefit" when combined with standard chemotherapy, a company official said.

View Full Article in:

RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA